ⅰa1期宫颈鳞癌临床与组织病理学分析分析-clinical and histopathological analysis of stage ⅰ a1 cervical squamous cell carcinoma.docx

中文摘要结论：IA1期子宫颈鳞癌的治疗已趋向选择更加保守的治疗方式；由于LVSI是影响IA1期子宫颈鳞癌患者预后的重要因素，对合并LVSI者应采用个体化的治疗方案，并加强监测。D2-40、CD34及β-catenin抗体进行免疫组化染色，其诊断淋巴管血管间隙浸润的可行性及明确其检出率高于HE染色，LVSI为一个不良预后指标，是估计病情进展，判断预后，并制订有针对性的治疗方案以及客观评价疗效的关键指标之一，而且淋巴管间隙浸润和血管间隙浸润同时阳性是影响预后的独立因素。【关键词】宫颈微小浸润癌；手术治疗；预后；淋巴血管间隙受累；免疫组化ABSTRACTPurposeThisresearchthroughtheretrospectiveanalysisof1995-2011,thestageⅠA1 cervicalsquamouscellcarcinomasinpatientswethclinicalandpathologicaldata,to exploretheprognosisofdifferenttreatments,andthroughtheD2-40,CD34and β-cateninantibodyimmunohistochemicalstainingtodetermineLVSI,clearblood clearanceofinvasionandlymphaticclearanceinfiltration,improvethediagnosticrateofLVSI,forthefutureclinicaltreatmentsforLVSI,forstageⅠA1periodclinicalstandardizedtreatmentofcervicalsquamouscarcinomaprovidereferenceopinions.Andindividualizedtreatment,accordingtothepatient’sconditionisnotonly moreeffectivetreatmentofearlycervicalsquamouscarcinoma,topreventfurther progressionlesions,andtoimprovethepatient’squalityoflife.ResearchMethods:Clinicopathologicaldataof346casesSCCdiagnosedbetweenNovember2nd 1995andDecember31th2011werereviewedandanalyzed.Figureoutthechangeof itsdiagnosisandtreatment,analyzetheprognosisofvarioustreatmentsandcases withlymphovascularspace invasion(LVSI).Slidesoutthe2009-2010casesofthestageⅠA1cervicalsquamouscarcinomasurgerypathological,pleasedepartmentapathologydoctorofdepartmentofhihgqualificationreview cases of pos toperativeslides,todeterminetheLVSI/HE.WithD2-40,CD34andβ-catenin antibodiesinⅠA1periodforimmunohistochemicalstainingincervicalspuamouscellcarcinomas(S-Pmethod),immunohistochemicalexperimentsdonein pathology,thefirsthospitalofimmunohistochemicalchamber.Results:Diagnosticmethod:2%(7/346)patientswerediagnosedwithloop electrosurgical excision procedure(LEEP), 44.5%(154/346 ）with cold knifeconization(CKC),1.7%（6/346）withvaginaltrachelectomy(VT),29.5%（102/346）withextrafascialhysterectomy(EH),21.4%（74/346）withmodifiedradicalhysterectomy(MRH),0.9%（3/346）withradicaltrachelectomy(RT).Fi